The Respiratory Distress Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Respiratory Distress Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Respiratory Distress Syndrome and features dormant and discontinued products.
GlobalData tracks 135 drugs in development for Respiratory Distress Syndrome by 123 companies/universities/institutes. The top development phase for Respiratory Distress Syndrome is preclinical with 74 drugs in that stage. The Respiratory Distress Syndrome pipeline has 128 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Respiratory Distress Syndrome pipeline products market are: Chiesi Farmaceutici, Pantherna Therapeutics and BioStem Technologies.
The key targets in the Respiratory Distress Syndrome pipeline products market include Tyrosine Protein Kinase SYK, Toll Like Receptor 4, and Glucocorticoid Receptor.
The key mechanisms of action in the Respiratory Distress Syndrome pipeline product include Glucocorticoid Receptor Agonist with two drugs in IND/CTA Filed. The Respiratory Distress Syndrome pipeline products include 16 routes of administration with the top ROA being Intravenous and 19 key molecule types in the Respiratory Distress Syndrome pipeline products market including Small Molecule, and Cell Therapy.
Respiratory Distress Syndrome overview
Respiratory distress syndrome (RDS) occurs in babies born early (premature) whose lungs are not fully developed. The earlier the infant is born, the more likely it is for them to have RDS and need extra oxygen and help breathing. It primarily affects premature infants due to insufficient surfactant, a lung-stabilizing substance. Without surfactant, the lungs collapse, causing breathing difficulties. Common in preterm births, symptoms include rapid breathing, grunting, nostril flaring, and cyanosis. Prompt diagnosis and treatment, often involving mechanical ventilation and surfactant replacement, are vital. While RDS is more prevalent in premature babies, it can also affect full-term infants with specific risk factors. Proactive neonatal care and surfactant therapy enhance lung function, significantly improving the prognosis for infants with RDS. Early detection and intervention are critical for optimal outcomes in managing respiratory distress in newborns.
For a complete picture of Respiratory Distress Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
